Congress caps inhaler costs at $15/month for asthma and COPD patients
S. 2756 — Affordable Inhalers and Nebulizers Act of 2025 · Filed by Angela Alsobrooks (D-MD) · 2 cosponsors · Introduced Sep 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps patient cost-sharing for prescription inhalers and related equipment at $15 per 30-day supply across private insurance, Medicare Part B, Medicare Part D, and creates a federal payment program for uninsured individuals. It applies to maintenance, reliever, and rescue inhalers used to treat asthma and COPD, and allows high-deductible and catastrophic health plans to waive deductibles for these drugs without losing their tax-advantaged status.
Why we flagged it
The bill's operative mechanism is a straightforward price ceiling ($15/month) on inhaler cost-sharing across all insurance types and a federal subsidy for the uninsured. It is not a deregulation, subsidy to manufacturers, or liability shield—it is a consumer price protection.
What the text implies
- The $15 cap applies to cost-sharing only, not to the underlying drug price; manufacturers retain pricing power, and insurers may respond by raising premiums or narrowing formularies to offset the capped copay.
- The federal payment program for uninsured individuals (Section 399V–8) is discretionary and subject to appropriations; without dedicated funding, it may be underfunded or unused, leaving uninsured patients without the promised backstop.
The full analysis lists 5 implications of this text.
Who stands to gain
Patients with asthma and COPD (primary beneficiaries—direct cost reduction); Pharmaceutical manufacturers of inhaler products (potential volume increase due to reduced cost barr; Healthcare providers administering inhalers to uninsured patients (federal reimbursement under Secti